Dr. Ansell on PD-1 Inhibitors in Hodgkin Lymphoma

Video

In Partnership With:

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

The use of PD-1 blockade drugs, such as nivolumab (Opdivo) or pembrolizumab (Keytruda), have proven to be promising in patients who have failed multiple prior therapies. There is an overexpression of PD-L1, which allows these patients to benefit from PD-1 treatment.

The CheckMate-039 study focused on using nivolumab to treat patients who had failed on prior lines of therapy. There were many different cohorts in this study, but the Hodgkin lymphoma cohort did particularly well, Ansell explains.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD